Securities code: Andon Health Co.Ltd(002432) securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022030 Andon Health Co.Ltd(002432)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and bear joint and several liabilities for false records, misleading statements or major omissions in the announcement.
1、 Introduction to abnormal fluctuations in stock trading
Andon Health Co.Ltd(002432) (hereinafter referred to as “the company”) stock (stock abbreviation: IX)
An medical, stock code: Andon Health Co.Ltd(002432) ) has accumulated more than 20% of the deviation value of the closing price increase for three consecutive trading days (March 11, March 14 and March 15, 2022). According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to the abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
The company checked the abnormal fluctuation of the company’s share price, and the results are as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company, controlling shareholders and actual controllers have no major events that should be disclosed but not disclosed or are in the planning stage.
3. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
4. Recently, the production and operation of the company is normal, and the internal and external business environment has not changed significantly. As of the United States
On March 9, 2022 local time, the company’s U.S. subsidiary has signed a contract for ihealth kit products
A total of 354276180 people were delivered by the opposite party (including the goods replaced due to damage and lost during transportation). So far, the US subsidiary of the company has fulfilled the delivery obligation of the above contract. Please refer to the above for details
Securities times, China Securities News and cninfo on March 11, 2022
（ http://www.cn.info.com.cn. ）Announcement on the progress of major contracts for the daily operation of the company’s U.S. subsidiaries (Announcement No. 2022026).
5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
6. The company does not violate the provisions on fair information disclosure.
3、 Whether there is a description of the situation that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
The company considers it necessary to give the following risk tips:
1. Risk of uncertainty in the development of the epidemic in the United States: the demand for the company’s antigen home self-test kit products is directly related to the development of the epidemic in the United States. Virus variation, vaccination and the introduction of covid-19 drugs all have an impact on the development of the epidemic. Therefore, the development of the epidemic in the future has strong uncertainty, This uncertainty may greatly affect the demand of kit products;
2. Uncertainty risk of market competition: at present, many companies’ antigen home self-test OTC kit products and covid-19 detection products used in POC use scenarios have been authorized by the U.S. FDA EUA. It cannot be ruled out that more companies will obtain such authorization and enter the market to sell kit products in the future. With the change of market competition situation, The existing market share and product price of a single enterprise may be impacted;
3. Risk of stock price fluctuation: from the technical indicators of the secondary market, as of March 15, Hithink Royalflush Information Network Co.Ltd(300033) shows that the company’s dynamic P / E ratio is 439.31; In terms of price to book ratio, as of the closing on March 15, the closing price of the company’s shares in the secondary market was 61.35 yuan / share, and the price to book ratio of the company shown in Hithink Royalflush Information Network Co.Ltd(300033) is 14.63. At present, the above data of the company is relatively higher than the historical stock price and P / E ratio of the company, which does not rule out the risk of falling of the company’s future stock price and the above indicators;
4. Exchange rate fluctuation risk: the company’s kit products are settled in US dollars this time, and the exchange rate fluctuation will have an impact on the company’s collection amount denominated in RMB and the amount of recognized operating revenue. In addition, with the expansion of sales scale, the number of foreign currencies held by the company will further increase. In view of the uncertainty of exchange rate fluctuations, the company will adjust the product sales price accordingly according to the exchange rate changes, and will consider locking the exchange rate by signing relevant agreements with banks to prevent the risk of large exchange rate fluctuations. However, if the fluctuation range is large in the short term, the company may have exchange losses, which will have an adverse impact on the company’s operating performance;
5. Quality risk: in the case of mass production, the batches of individual products may have quality problems, leading to the risk of return or even recall;
6. Buyer’s risk: up to now, the delivery obligation agreed in the company’s contract has been fulfilled, and payment will be arranged after the buyer’s inspection and receipt. At present, the contract is under normal performance and the buyer has the ability to perform the contract, but there are still risks of the buyer such as delayed payment before all the payment is received.
The company will fulfill the obligation of information disclosure in accordance with the relevant provisions of information disclosure of listed companies. Please pay attention to risks and invest rationally.
It is hereby announced
Andon Health Co.Ltd(002432) board of directors
March 16, 2022
